Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

UroGen Pharma (URGN) EBIT (2017 - 2025)

UroGen Pharma (URGN) has disclosed EBIT for 9 consecutive years, with $70.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 73.58% year-over-year to $70.5 million, compared with a TTM value of -$35.3 million through Dec 2025, down 23.68%, and an annual FY2025 reading of -$35.3 million, down 23.68% over the prior year.
  • EBIT was $70.5 million for Q4 2025 at UroGen Pharma, up from -$27.4 million in the prior quarter.
  • Across five years, EBIT topped out at $70.5 million in Q4 2025 and bottomed at -$41.4 million in Q2 2025.
  • Average EBIT over 5 years is -$6.8 million, with a median of -$20.3 million recorded in 2022.
  • The sharpest move saw EBIT skyrocketed 273.27% in 2021, then tumbled 67.98% in 2024.
  • Year by year, EBIT stood at $47.2 million in 2021, then fell by 28.19% to $33.9 million in 2022, then dropped by 16.51% to $28.3 million in 2023, then surged by 43.38% to $40.6 million in 2024, then surged by 73.58% to $70.5 million in 2025.
  • Business Quant data shows EBIT for URGN at $70.5 million in Q4 2025, -$27.4 million in Q3 2025, and -$41.4 million in Q2 2025.